Yahoo
BSE INR

Aurobindo Pharma Limited (AUROPHARMA.BO)

1,677.80 +22.80 (+1.38%)
At close: October 30 at 3:52:15 PM GMT+5:30
Chart Range Bar
Loading chart for AUROPHARMA.BO
  • Previous Close 1,655.00
  • Open 1,650.10
  • Bid 1,667.90 x --
  • Ask --
  • Day's Range 1,650.10 - 1,686.20
  • 52 Week Range 994.35 - 1,686.20
  • Volume 14,748
  • Avg. Volume 41,090
  • Market Cap (intraday) 975.954B
  • Beta (5Y Monthly) 0.05
  • PE Ratio (TTM) 28.49
  • EPS (TTM) 58.89
  • Earnings Date Nov 4, 2026
  • Forward Dividend & Yield 4.00 (0.33%)
  • Ex-Dividend Date Aug 8, 2025
  • 1y Target Est 1,318.62

Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company has operations in India, the United States, Europe, Puerto Rico, and internationally. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

www.aurobindo.com

27,707

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 82.86B
Earnings 8.48B
Profit Margin 10.24%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
20B
40B
60B
80B
10.3%
10.4%
10.5%
10.6%
10.7%

Analyst Insights

View More

Analyst Price Targets

730.00 Low
1,318.62 Average
1,677.80 Current
1,640.00

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    10.53%

  • Return on Assets (ttm)

    6.31%

  • Return on Equity (ttm)

    10.38%

  • Revenue (ttm)

    325.14B

  • Net Income Avi to Common (ttm)

    34.22B

  • Diluted EPS (ttm)

    58.89

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    88.92B

  • Total Debt/Equity (mrq)

    22.25%

  • Levered Free Cash Flow (ttm)

    18.38B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: